Compare Neurocrine Biosciences Inc (NBIX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Verizon Communications Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Verizon Communications Inc trades at $41.65 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 13.4× Neurocrine Biosciences Inc's market cap, and Verizon Communications Inc pays a 6.11% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Verizon Communications Inc for 109 Days on average.
| NBIX | VZ | |
|---|---|---|
Market Cap | $14.36B | $192.57B |
Volume | 1,237,180 | 20,940,094 |
Sector | Health | Media |
52-Week High | $185.50 | $51.45 |
52-Week Low | $123.10 | $38.40 |
Typical Hold Time | 23 Days | 109 Days |
Enterprise Value | $14.37B | $379.28B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Verizon (VZ) trades at $46.35, up 1.27% today, with a bearish technical signal despite recent earnings beats. The stock shows stable revenue around $138B annually with strong cash flow generation of $37.1B from operations in 2025. Valuation metrics appear reasonable with P/E of 12.07 and EV/EBITDA of 7.9, while the company maintains a solid dividend yield supported by consistent cash flows.
Outlook remains stable with moderate growth prospects amid competitive telecom landscape. Investment appeal centers on dividend reliability and defensive positioning, though technical weakness and modest revenue growth present near-term challenges. Risks include intense competition and capital expenditure requirements for network expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
